# CATX — Perspective Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** CATX  
**Sources:** 24  
**Published:** 2026-10-17  
**Canonical:** https://app.k3vl4r.com/research/deep-research-catx-perspective-therapeutics-inc-catalysts-narrative-ri-7884

---

# Perspective Therapeutics, Inc. (NYSE American: CATX) — Research Snapshot

As of the Oct 16, 2026 close, CATX traded around **$2.17** (down ~7.3% that day), with a market capitalization of roughly **$247.7M–$267.1M** (sources differ) and a 52-week range of **$1.96–$6.16** [[8]](https://wallstsmart.com/stock/CATX/price-targets) [[11]](https://tickernerd.com/stock/catx-forecast/) [[14]](https://stockanalysis.com/stocks/catx/forecast/) [[20]](https://finance.yahoo.com/quote/CATX/) [[26]](https://stocktwits.com/symbol/CATX). It carries a high beta (1.85), negative TTM EPS (~-$1.33), ~$236.9M in cash, and no meaningful trailing revenue [[8]](https://wallstsmart.com/stock/CATX/price-targets) [[20]](https://finance.yahoo.com/quote/CATX/) [[24]](https://www.morningstar.com/stocks/xase/catx/quote). It is a clinical-stage radiopharmaceutical developer using its lead-212 (²¹²Pb) alpha-therapy platform [[3]](https://www.marketscreener.com/news/perspective-therapeutics-announces-acceptance-of-212pb-vmt01-data-for-presentation-at-sitc-2026-ce785ddbd98df722) [[24]](https://www.morningstar.com/stocks/xase/catx/quote).

## Key Recent Catalysts (July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-catx-perspective-therapeutics-inc-catalysts-narrative-ri-7884 (free to sign up)._
